KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Deyan Y Yosifov, Sandra Robrecht, Adam Giza, Palash C Maity, Armin Riecke, Christof Schneider, Billy M C Jebaraj, Rashmi P Dheenadayalan, Hassan Jumaa, Marc Young, Manish Kumar, Lothar Müller, Ursula Vehling-Kaiser, Michael Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Petra Langerbeins, Eugen Tausch, Stephan Stilgenbauer

Hemasphere 10(6) e70385

PMID42306064
PMCIDPMC13266578
DOI10.1002/hem3.70385
发表日期2026-06-17
摘要

摘要

IGLV3-21R110 is a point mutation enabling autonomous B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors. Here, we analyzed samples from the phase 3 CLL12 study that compared ibrutinib vs. placebo in untreated early-stage CLL patients with intermediate to very high risk of disease progression, while patients with low risk of disease progression were allocated to watch-and-wait (w&w). Four detection methods (targeted next-generation sequencing, Sanger sequencing, multiplex IGLV3-21R110-specific PCR, and flow cytometry) were compared, yielding highly consistent results. Overall, 34/515 (6.6%) patients had productive IGLV3-21 rearrangements: 5/152 (3.3%) in w&w, 15/181 (8.3%) in placebo, and 14/182 (7.7%) in the ibrutinib group. Of these, 25 were IGLV3-21R110-positive (3/5, 12/15, and 10/14). IGLV3-21R110 was associated with shorter event-free survival (EFS) across all arms: w&w (hazard ratio [HR] 17.03, 95% confidence interval [CI 95%]: 4.99-58.13, P < 0.001), placebo (HR 2.31, CI 95%: 1.16-4.6, P = 0.017), and ibrutinib (HR 2.99, CI 95%: 1.17-7.65, P = 0.023). Multivariable analysis identified IGLV3-21R110 as an independent prognostic factor for shorter EFS (HR 3.18, CI 95%: 1.73-5.83, P < 0.001). Notably, IGLV3-21R110 was associated with reduced clinical effectiveness of ibrutinib. Ca2+-flux and cell viability assays using patient-derived BCRs expressed in murine B-cells confirmed reduced ibrutinib efficacy in IGLV3-21R110 cases, especially regarding inhibition of antigen-stimulated signaling. In summary, IGLV3-21R110 is an independent prognostic factor for shorter EFS in early-stage CLL and reduces ibrutinib effectiveness clinically and in vitro.

KM 提取结果

3 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2 Kaplan–Meier plot and risk table estimating time to first treatment in the watch & wait and placebo cohorts of the CLL12 trial. The watch & wait group is depicted in black and the placebo cohort is shown in green. Within each of the two groups, patients expressing IGLV3‐21 R110 (dashed lines) are compared against patients who do not express IGLV3‐21 R110 (solid lines). Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test.

Time_to_first_treatment_from_diagnosis_months_

Time to first treatment from diagnosis

Figure 2 · Panel Time_to_first_treatment_from_diagnosis_months_

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel Time_to_first_treatment_from_diagnosis_months_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure6 个面板

Figure 3

Figure 3 Kaplan–Meier plots and risk tables estimating event‐free and overall survival in the CLL12 trial. (A , B) EFS (A) and OS (B) of patients from all trial arms. The comparison is carried out between patients expressing IGLV3‐21 R110 (black) and patients not expressing IGLV3‐21 light chains (blue) or expressing IGLV3‐21 G110 (green), taken as one group. (C , D) EFS (C) and OS (D) of patients from the placebo (green) and ibrutinib (blue) arms. Within each treatment arm, patients expressing IGLV3‐21 R110 (dashed lines) are compared against patients who do not express IGLV3‐21 R110 (solid lines). (E , F) EFS (E) and OS (F) of patients from the observational arm. The comparison is carried out between patients expressing IGLV3‐21 R110 (black) and patients not expressing IGLV3‐21 light chains (blue) or expressing IGLV3‐21 G110 (green), taken as one group. Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test. Statistics for all possible pairwise comparisons in (A , B) and (E , F) are provided in Supporting Information S1: Tables S5–S8.

A

EFS

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 2:off origin start曲线 2:extreme upward reversal曲线 3:off origin start
查看结果
B

OS

Figure 3 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
C

EFS

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 4 条,实际恢复 2 条曲线 1:extreme upward reversal曲线 2:extreme jump曲线 2:off origin start
查看结果
D

OS

Figure 3 · Panel D

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme jump曲线 2:extreme upward reversal曲线 3:extreme jump
查看结果
E

EFS

Figure 3 · Panel E

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
F

OS

Figure 3 · Panel F

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure4 个面板

Figure 4

Figure 4 Kaplan–Meier plots and risk tables estimating event‐free and overall survival in the CLL12 trial. (A , B) EFS (A) and OS (B) of patients from all trial arms stratified according to their IGHV mutational status—unmutated (green and blue) or mutated (black and red). Within each of the two groups, patients expressing IGLV3‐21 R110 (green or black, respectively) are compared against patients who do not express IGLV3‐21 R110 (blue or red, respectively). (C , D) EFS (C) and OS (D) of patients from the ibrutinib arm separated according to their IGHV mutational status— unmutated (green and blue) or mutated (black and red). Within each of the two groups, patients expressing IGLV3‐21 R110 (green or black, respectively) are compared against patients who do not express IGLV3‐21 R110 (blue or red, respectively). Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test. Statistics for all possible pairwise comparisons are provided in Supporting Information S1: Tables S9–S12.

_A_

EFS

Figure 4 · Panel _A_

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel _A_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 3:extreme jump曲线 3:extreme upward reversal
查看结果
_B_

OS

Figure 4 · Panel _B_

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel _B_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 4:off origin start
查看结果
_C_

EFS

Figure 4 · Panel _C_

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel _C_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal
查看结果
_D_

OS

Figure 4 · Panel _D_

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel _D_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal曲线 4:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Prevalence of IGLV3‐21 R110 in the CLL12 cohort and correlation with other genetic markers . (A) Prevalence of the IGLV3‐21 rearrangement in the three arms of the CLL12 trial. (B) Prevalence of the G110R mutation in the subgroup of patients with the IGLV3‐21 rearrangement. (C) Combined box/scatter plots showing IGHV mutational load as the percentage of identity to the respective germline IGHV sequence. The dashed line depicts the threshold of 98% used for classifying CLL as M‐CLL or U‐CLL. Data from 534 IGHV‐defined CLL clones are shown, as some patients had more than one clone. ****P < 0.0001, Welch's ANOVA with Dunnett's T3 all‐pairs comparison post‐hoc test. (D) Used IGLJ segment and presence or absence of the G110R mutation among the cases expressing IGLV3‐21. (E) Circos plot showing IGHV genes used by CLL clones classified as either M‐CLL, U‐CLL, or IGLV3‐21 R110 ( n = 534, as in (C) ). (F) Presence of specific chromosome aberrations and gene mutations in cases with and without IGLV3‐21 R110 . **P < 0.01, Fisher's exact test with Benjamini–Hochberg correction. (G) Oncoprint plot of the most common driver alterations in CLL cases with a productive IGLV3‐21 rearrangement. Grouping is according to the absence or presence of the G110R mutation, and additional displayed parameters include belonging to subset #2 and IGHV mutational status. Patients with two CLL clones of diverging IGHV mutational status are classified as having undetermined overall status. Percentages represent the proportion of patients carrying each specific driver alteration among IGLV3‐21 G110 cases (left) and IGLV3‐21 R110 cases (right).
非 KM Figure
Figure 5Figure 5 IGLV3‐21 R110 reduces the effectiveness of ibrutinib. (A) Ca 2+ influx in TKO‐EST cells expressing a BCR from CLL patient 1 (IGLV3‐21 G110 , left panels) or from CLL patient 4 (IGLV3‐21 R110 , right panels). Cells were pre‐treated with vehicle or ibrutinib (100 or 500 nM, as indicated). On each density plot, the first arrow denotes the addition of 4‐hydroxytamoxifen (used to induce the ERT2‐SLP65 fusion protein and enable measurement of autonomous signaling) and the second arrow denotes the addition of anti‐κ/λ antibodies for measurement of antigen‐stimulated signaling. Additional data obtained with all used BCRs are provided in Supporting Information S1: Figures S7–S9. (B , C) Summarized data from the experiments described in (A) after normalization of the Ca 2+ influx AUC to the mean of each respective untreated control. (B) Inhibition of autonomous signaling. (C) Inhibition of antigen‐stimulated signaling. Mean values are denoted by dashes. Statistical significance was evaluated using repeated‐measures two‐way ANOVA with uncorrected Fisher's LSD test. *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. (D) Survival of TKO‐EST cells expressing BCRs from CLL patients with IGLV3‐21 G110 or IGLV3‐21 R110 light chains after treatment with ibrutinib for 48 h. Cell survival was measured using the CellTiter‐Glo® cell viability assay using a minimum of three replicates for each BCR. Each curve (four‐parameter logistic model) corresponds to a different patient BCR. An autonomously active BCR from a previously analyzed subset #201 CLL patient was used as a positive control. A BCR isolated from a naïve B‐cell from a healthy donor (IGHV4‐39/IGKV3‐15) was used as a negative control for autonomous signaling. Statistical evaluation was performed by 2‐way ANOVA and Šidák's multiple comparisons test, where the IGLV3‐21 G110 and IGLV3‐21 R110 groups were compared at each ibrutinib concentration level. *P < 0.05; ****P < 0.0001. Absolute IC 50 values with 95% confidence intervals were determined from each curve and then geometrically averaged within each group.
非 KM Figure